<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20240814161035&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20240814161035&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 14 Aug 2024 20:10:36 +0000</lastbuilddate>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Epicardial and Pericardial Fat-Separated But Under the Same Roof-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39141398/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240814161035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 14. doi: 10.1001/jamacardio.2024.2427. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39141398/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240814161035&v=2.18.0.post9+e462414">39141398</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2427>10.1001/jamacardio.2024.2427</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39141398</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Joel T Rämö</dc:creator>
<dc:creator>Patrick T Ellinor</dc:creator>
<dc:creator>James P Pirruccello</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Epicardial and Pericardial Fat-Separated But Under the Same Roof-Reply</dc:title>
<dc:identifier>pmid:39141398</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2427</dc:identifier>
</item>
<item>
<title>Routine Protamine Administration for Bleeding in Transcatheter Aortic Valve Implantation: The ACE-PROTAVI Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39141396/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240814161035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In the ACE-PROTAVI randomized clinical trial, routine administration of protamine increased the rate of hemostasis success and decreased TTH. The beneficial effect of protamine was reflected in a reduction in minor vascular complications, procedural time, and postprocedural hospital stay duration in patients receiving routine protamine compared with patients receiving placebo.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 14. doi: 10.1001/jamacardio.2024.2454. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Vascular complications after transfemoral transcatheter aortic valve implantation (TAVI) remain an important cause of procedure-related morbidity. Routine reversal of anticoagulation with protamine at the conclusion of transfemoral TAVI could reduce complications, but data remain scarce.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the efficacy and safety of routine protamine administration after transfemoral TAVI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The ACE-PROTAVI trial was an investigator-initiated, double-blind, placebo-controlled randomized clinical trial performed at 3 Australian hospitals between December 2021 and June 2023 with a 1-year follow-up period. All patients accepted for transfemoral TAVI by a multidisciplinary heart team were eligible for enrollment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Eligible patients were randomized 1:1 between routine protamine administration and placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The coprimary outcomes were the rate of hemostasis success and time to hemostasis (TTH), presented as categorical variables and compared with a χ2 test or as continuous variables as mean (SD) or median (IQR), depending on distribution. The major secondary outcome was a composite of all-cause death, major and minor bleeding complications, and major and minor vascular complications after 30 days, reported in odds ratios (ORs) with 95% CIs and P values.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study population consisted of 410 patients: 199 patients in the protamine group and 211 in the placebo group. The median (IQR) patient age in the protamine group was 82 (77-85) years, and 68 of 199 patients receiving protamine (34.2%) were female. The median (IQR) patient age in the placebo group was 80 (75-85) years, and 89 of 211 patients receiving the placebo (42.2%) were female. Patients receiving up-front protamine administration had a higher rate of hemostasis success (188 of 192 patients [97.9%]) than patients in the placebo group (186 of 203 patients [91.6%]; absolute risk difference, 6.3%; 95% CI, 2.0%-10.6%; P = .006); in addition, patients receiving up-front protamine had a shorter median (IQR) TTH (181 [120-420] seconds vs 279 [122-600] seconds; P = .002). Routine protamine administration resulted in a reduced risk of the composite outcome in the protamine group (10 of 192 [5.2%]) vs the placebo group (26 of 203 [12.8%]; OR, 0.37; 95% CI, 0.1-0.8; P = .01). This difference was predominantly driven by the difference in the prevalence of minor vascular complications. There were no adverse events associated with protamine use.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In the ACE-PROTAVI randomized clinical trial, routine administration of protamine increased the rate of hemostasis success and decreased TTH. The beneficial effect of protamine was reflected in a reduction in minor vascular complications, procedural time, and postprocedural hospital stay duration in patients receiving routine protamine compared with patients receiving placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12621001261808.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39141396/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240814161035&v=2.18.0.post9+e462414">39141396</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2454>10.1001/jamacardio.2024.2454</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39141396</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Pieter A Vriesendorp</dc:creator>
<dc:creator>Shane Nanayakkara</dc:creator>
<dc:creator>Samuel Heuts</dc:creator>
<dc:creator>Jocasta Ball</dc:creator>
<dc:creator>Jaya Chandrasekar</dc:creator>
<dc:creator>Ronald Dick</dc:creator>
<dc:creator>Kawa Haji</dc:creator>
<dc:creator>Nay Min Htun</dc:creator>
<dc:creator>David McGaw</dc:creator>
<dc:creator>Samer Noaman</dc:creator>
<dc:creator>Sonny Palmer</dc:creator>
<dc:creator>Sesto Cairo</dc:creator>
<dc:creator>Mark Shulman</dc:creator>
<dc:creator>Enjarn Lin</dc:creator>
<dc:creator>Stuart Hastings</dc:creator>
<dc:creator>Benedict Waldron</dc:creator>
<dc:creator>George Proimos</dc:creator>
<dc:creator>Kean H Soon</dc:creator>
<dc:creator>Matias B Yudi</dc:creator>
<dc:creator>Adam Zimmet</dc:creator>
<dc:creator>Dion Stub</dc:creator>
<dc:creator>Antony S Walton</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Routine Protamine Administration for Bleeding in Transcatheter Aortic Valve Implantation: The ACE-PROTAVI Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39141396</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2454</dc:identifier>
</item>
<item>
<title>Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction: The AMETHYST Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39141378/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240814161035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial show that despite substantial SUA lowering, verinurad plus allopurinol did not result in a significant improvement in peak VO2 or symptoms compared with allopurinol monotherapy or placebo in HFpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 14. doi: 10.1001/jamacardio.2024.2435. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Elevated serum uric acid (SUA) level may contribute to endothelial dysfunction; therefore, SUA is an attractive target for heart failure with preserved ejection fraction (HFpEF). However, to the authors' knowledge, no prior randomized clinical trials have evaluated SUA lowering in HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate the efficacy and safety of the novel urate transporter-1 inhibitor, verinurad, in patients with HFpEF and elevated SUA level.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a phase 2, double-blind, randomized clinical trial (32-week duration) conducted from May 2020 to April 2022. The study took place at 59 centers in 12 countries and included patients 40 years and older with HFpEF and SUA level greater than 6 mg/dL. Data were analyzed from August 2022 to May 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Eligible patients were randomized 1:1:1 to once-daily, oral verinurad, 12 mg, plus allopurinol, 300 mg; allopurinol, 300 mg, monotherapy; or placebo for 24 weeks after an 8-week titration period. Allopurinol was combined with verinurad to prevent verinurad-induced urate nephropathy, and the allopurinol monotherapy group was included to account for allopurinol effects in the combination therapy group. All patients received oral colchicine, 0.5 to 0.6 mg, daily for the first 12 weeks after randomization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Key end points included changes from baseline to week 32 in peak oxygen uptake (VO2), Kansas City Cardiomyopathy Questionnaire total symptom score (KCCQ-TSS), and SUA level; and safety/tolerability (including adjudicated cardiovascular events).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 159 randomized patients (53 per treatment group; median [IQR] age, 71 [40-86] years; 103 male [65%]) with median (IQR) N-terminal pro-brain natriuretic peptide level of 527 (239-1044) pg/mL and SUA level of 7.5 (6.6-8.4) mg/dL, verinurad plus allopurinol (mean change, -59.6%; 95% CI, -64.4% to -54.2%) lowered SUA level to a greater extent than allopurinol (mean change, -37.6%; 95% CI, -45.3% to -28.9%) or placebo (mean change, 0.8%; 95% CI, -11.8% to 15.2%; P &lt; .001). Changes in peak VO2 (verinurad plus allopurinol, 0.27 mL/kg/min; 95% CI, -0.56 to 1.10 mL/kg/min; allopurinol, -0.17 mL/kg/min; 95% CI, -1.03 to 0.69 mL/kg/min; placebo, 0.37 mL/kg/min; 95% CI, -0.45 to 1.19 mL/kg/min) and KCCQ-TSS (verinurad plus allopurinol, 4.3; 95% CI, 0.3-8.3; allopurinol, 4.5; 95% CI, 0.3-8.6; placebo, 1.2; 95% CI, -3.0 to 5.3) were similar across groups. There were no adverse safety signals. Deaths or cardiovascular events occurred in 3 patients (5.7%) in the verinurad plus allopurinol group, 8 patients (15.1%) in the allopurinol monotherapy group, and 6 patients (11.3%) in the placebo group.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial show that despite substantial SUA lowering, verinurad plus allopurinol did not result in a significant improvement in peak VO2 or symptoms compared with allopurinol monotherapy or placebo in HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04327024.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39141378/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240814161035&v=2.18.0.post9+e462414">39141378</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2435>10.1001/jamacardio.2024.2435</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39141378</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Dalane W Kitzman</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Robert J Mentz</dc:creator>
<dc:creator>Gregory D Lewis</dc:creator>
<dc:creator>Shira Perl</dc:creator>
<dc:creator>Robin Myte</dc:creator>
<dc:creator>Grace Kaguthi</dc:creator>
<dc:creator>C David Sjöström</dc:creator>
<dc:creator>Christian Källgren</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction: The AMETHYST Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39141378</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2435</dc:identifier>
</item>
<item>
<title>Epicardial and Pericardial Fat-Separated But Under the Same Roof</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39141368/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240814161035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 14. doi: 10.1001/jamacardio.2024.2424. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39141368/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240814161035&v=2.18.0.post9+e462414">39141368</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2424>10.1001/jamacardio.2024.2424</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39141368</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Gianluca Iacobellis</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Epicardial and Pericardial Fat-Separated But Under the Same Roof</dc:title>
<dc:identifier>pmid:39141368</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2424</dc:identifier>
</item>
<item>
<title>Error in Figure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39141066/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240814161035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 1;9(8):760. doi: 10.1001/jamacardio.2024.2323.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39141066/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240814161035&v=2.18.0.post9+e462414">39141066</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2323>10.1001/jamacardio.2024.2323</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39141066</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-14</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Error in Figure</dc:title>
<dc:identifier>pmid:39141066</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2323</dc:identifier>
</item>
<item>
<title>JAMA Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39141065/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240814161035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 1;9(8):678. doi: 10.1001/jamacardio.2023.3671.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39141065/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240814161035&v=2.18.0.post9+e462414">39141065</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3671>10.1001/jamacardio.2023.3671</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39141065</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-14</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology</dc:title>
<dc:identifier>pmid:39141065</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3671</dc:identifier>
</item>
<item>
<title>Cardiorenal Outcomes in Middle-Aged and Older Adults With Type 1 and Type 2 Diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39140954/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240814161035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 7:S0735-1097(24)07747-7. doi: 10.1016/j.jacc.2024.06.024. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39140954/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240814161035&v=2.18.0.post9+e462414">39140954</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.024>10.1016/j.jacc.2024.06.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39140954</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>John W Ostrominski</dc:creator>
<dc:creator>So Mi Jemma Cho</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Michael C Honigberg</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cardiorenal Outcomes in Middle-Aged and Older Adults With Type 1 and Type 2 Diabetes</dc:title>
<dc:identifier>pmid:39140954</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.024</dc:identifier>
</item>
<item>
<title>From arteries to veins: the expanding role of lipid-lowering drugs in preventing thrombosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39140442/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240814161035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 14:ehae492. doi: 10.1093/eurheartj/ehae492. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39140442/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240814161035&v=2.18.0.post9+e462414">39140442</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae492>10.1093/eurheartj/ehae492</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39140442</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Stephan Nopp</dc:creator>
<dc:creator>Cihan Ay</dc:creator>
<dc:creator>Ingrid Pabinger</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>From arteries to veins: the expanding role of lipid-lowering drugs in preventing thrombosis</dc:title>
<dc:identifier>pmid:39140442</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae492</dc:identifier>
</item>
<item>
<title>Restoring Atrial T-Tubules Augments Systolic Ca Upon Recovery From Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39140440/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240814161035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: We show that recovery from HF restores atrial t-tubules, and this promotes recovery of I(Ca-L), sarcoplasmic reticulum Ca^(2+) content, and systolic Ca^(2+). We demonstrate an important role for myotubularin in t-tubule restoration. Our findings reveal a new and viable therapeutic strategy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Aug 14. doi: 10.1161/CIRCRESAHA.124.324601. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Transverse (t)-tubules drive the rapid and synchronous Ca<sup>2+</sup> rise in cardiac myocytes. The virtual complete atrial t-tubule loss in heart failure (HF) decreases Ca<sup>2+</sup> release. It is unknown if or how atrial t-tubules can be restored and how this affects systolic Ca<sup>2+</sup>.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: HF was induced in sheep by rapid ventricular pacing and recovered following termination of rapid pacing. Serial block-face scanning electron microscopy and confocal imaging were used to study t-tubule ultrastructure. Function was assessed using patchclamp, Ca<sup>2+</sup>, and confocal imaging. Candidate proteins involved in atrial t-tubule recovery were identified by western blot and expressed in rat neonatal ventricular myocytes to determine if they altered t-tubule structure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Atrial t-tubules were lost in HF but reappeared following recovery from HF. Recovered t-tubules were disordered, adopting distinct morphologies with increased t-tubule length and branching. T-tubule disorder was associated with mitochondrial disorder. Recovered t-tubules were functional, triggering Ca<sup>2+</sup> release in the cell interior. Systolic Ca<sup>2+</sup>, <i>I</i><sub>Ca-L</sub>, sarcoplasmic reticulum Ca<sup>2+</sup> content, and SERCA function were restored following recovery from HF. Confocal microscopy showed fragmentation of ryanodine receptor staining and movement away from the z-line in HF, which was reversed following recovery from HF. Acute detubulation, to remove recovered t-tubules, confirmed their key role in restoration of the systolic Ca<sup>2+</sup> transient, the rate of Ca<sup>2+</sup> removal, and the peak L-type Ca<sup>2+</sup> current. The abundance of telethonin and myotubularin decreased during HF and increased during recovery. Transfection with these proteins altered the density and structure of tubules in neonatal myocytes. Myotubularin had a greater effect, increasing tubule length and branching, replicating that seen in the recovery atria.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We show that recovery from HF restores atrial t-tubules, and this promotes recovery of <i>I</i><sub>Ca-L</sub>, sarcoplasmic reticulum Ca<sup>2+</sup> content, and systolic Ca<sup>2+</sup>. We demonstrate an important role for myotubularin in t-tubule restoration. Our findings reveal a new and viable therapeutic strategy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39140440/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240814161035&v=2.18.0.post9+e462414">39140440</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324601>10.1161/CIRCRESAHA.124.324601</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39140440</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Jessica L Caldwell</dc:creator>
<dc:creator>Jessica D Clarke</dc:creator>
<dc:creator>Charlotte E R Smith</dc:creator>
<dc:creator>Christian Pinali</dc:creator>
<dc:creator>Callum J Quinn</dc:creator>
<dc:creator>Charles M Pearman</dc:creator>
<dc:creator>Aiste Adomaviciene</dc:creator>
<dc:creator>Emma J Radcliffe</dc:creator>
<dc:creator>Amy E Watkins</dc:creator>
<dc:creator>Margaux A Horn</dc:creator>
<dc:creator>Elizabeth F Bode</dc:creator>
<dc:creator>George W P Madders</dc:creator>
<dc:creator>Mark Eisner</dc:creator>
<dc:creator>David A Eisner</dc:creator>
<dc:creator>Andrew W Trafford</dc:creator>
<dc:creator>Katharine M Dibb</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Restoring Atrial T-Tubules Augments Systolic Ca Upon Recovery From Heart Failure</dc:title>
<dc:identifier>pmid:39140440</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324601</dc:identifier>
</item>
<item>
<title>A very rare complication of transcatheter aortic valve replacement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39140439/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240814161035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 14:ehae316. doi: 10.1093/eurheartj/ehae316. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39140439/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240814161035&v=2.18.0.post9+e462414">39140439</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae316>10.1093/eurheartj/ehae316</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39140439</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Lin Bai</dc:creator>
<dc:creator>Yuan Feng</dc:creator>
<dc:creator>Mao Chen</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A very rare complication of transcatheter aortic valve replacement</dc:title>
<dc:identifier>pmid:39140439</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae316</dc:identifier>
</item>
<item>
<title>Device-measured physical activity and cardiac structure by magnetic resonance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39140328/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240814161035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: High levels of device-measured physical activity were associated with cardiac remodelling within normal ranges.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 14:ehae506. doi: 10.1093/eurheartj/ehae506. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Although extreme cardiac adaptions mirroring phenotypes of cardiomyopathy have been observed in endurance athletes, adaptions to high levels of physical activity within the wider population are under-explored. Therefore, in this study, associations between device-measured physical activity and clinically relevant cardiac magnetic resonance volumetric indices were investigated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Individuals without known cardiovascular disease or hypertension were included from the UK Biobank. Cardiac magnetic resonance data were collected between 2015 and 2019, and measures of end-diastolic chamber volume, left ventricular (LV) wall thickness, and LV ejection fraction were extracted. Moderate-to-vigorous-intensity physical activity (MVPA), vigorous-intensity physical activity (VPA), and total physical activity were assessed via wrist-worn accelerometers.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 5977 women (median age and MVPA: 62 years and 46.8 min/day, respectively) and 4134 men (64 years and 49.8 min/day, respectively) were included. Each additional 10 min/day of MVPA was associated with a 0.70 [95% confidence interval (CI): 0.62, 0.79] mL/m2 higher indexed LV end-diastolic volume (LVEDVi) in women and a 1.08 (95% CI: 0.95, 1.20) mL/m2 higher LVEDVi in men. However, even within the top decile of MVPA, LVEDVi values remained within the normal ranges [79.1 (95% CI: 78.3, 80.0) mL/m2 in women and 91.4 (95% CI: 90.1, 92.7) mL/m2 in men]. Associations with MVPA were also observed for the right ventricle and the left/right atria, with an inverse association observed for LV ejection fraction. Associations of MVPA with maximum or average LV wall thickness were not clinically meaningful. Results for total physical activity and VPA mirrored those for MVPA.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: High levels of device-measured physical activity were associated with cardiac remodelling within normal ranges.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39140328/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240814161035&v=2.18.0.post9+e462414">39140328</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae506>10.1093/eurheartj/ehae506</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39140328</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Thomas Yates</dc:creator>
<dc:creator>Cameron Razieh</dc:creator>
<dc:creator>Joe Henson</dc:creator>
<dc:creator>Alex V Rowlands</dc:creator>
<dc:creator>Jonathan Goldney</dc:creator>
<dc:creator>Gaurav S Gulsin</dc:creator>
<dc:creator>Melanie J Davies</dc:creator>
<dc:creator>Kamlesh Khunti</dc:creator>
<dc:creator>Francesco Zaccardi</dc:creator>
<dc:creator>Gerry P McCann</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Device-measured physical activity and cardiac structure by magnetic resonance</dc:title>
<dc:identifier>pmid:39140328</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae506</dc:identifier>
</item>
<item>
<title>Targeting Cyclophilin A in the Cardiac Microenvironment Preserves Heart Function and Structure in Failing Hearts</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39140165/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240814161035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study provides strong evidence of the pathogenic role of eCyPA in remodeling, myocardial stiffening, and dysfunction in heart failure. The findings suggest that antibody-based inhibition of eCyPA may offer a novel therapeutic strategy for nonischemic heart failure. Further research is needed to evaluate the translational potential of these interventions in human patients with cardiac hypertrophy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Aug 14. doi: 10.1161/CIRCRESAHA.124.324812. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiac hypertrophy is characterized by remodeling of the myocardium, which involves alterations in the ECM (extracellular matrix) and cardiomyocyte structure. These alterations critically contribute to impaired contractility and relaxation, ultimately leading to heart failure. Emerging evidence implicates that extracellular signaling molecules are critically involved in the pathogenesis of cardiac hypertrophy and remodeling. The immunophilin CyPA (cyclophilin A) has been identified as a potential culprit. In this study, we aimed to unravel the interplay between eCyPA (extracellular CyPA) and myocardial dysfunction and evaluate the therapeutic potential of inhibiting its extracellular accumulation to improve heart function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Employing a multidisciplinary approach encompassing in silico, in vitro, in vivo, and ex vivo experiments we studied a mouse model of cardiac hypertrophy and human heart specimen to decipher the interaction of CyPA and the cardiac microenvironment in highly relevant pre-/clinical settings. Myocardial expression of CyPA (immunohistology) and the inflammatory transcriptome (NanoString) was analyzed in human cardiac tissue derived from patients with nonischemic, noninflammatory congestive heart failure (n=187). These analyses were paralleled by a mouse model of Ang (angiotensin) II-induced heart failure, which was assessed by functional (echocardiography), structural (immunohistology, atomic force microscopy), and biomolecular (Raman spectroscopy) analyses. The effect of inhibiting eCyPA in the cardiac microenvironment was evaluated using a newly developed neutralizing anti-eCyPA monoclonal antibody.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We observed a significant accumulation of eCyPA in both human and murine-failing hearts. Importantly, higher eCyPA expression was associated with poor clinical outcomes in patients (<i>P</i>=0.043) and contractile dysfunction in mice (Pearson correlation coefficient, -0.73). Further, myocardial expression of eCyPA was critically associated with an increase in myocardial hypertrophy, inflammation, fibrosis, stiffness, and cardiac dysfunction in vivo. Antibody-based inhibition of eCyPA prevented (Ang II)-induced myocardial remodeling and dysfunction in mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study provides strong evidence of the pathogenic role of eCyPA in remodeling, myocardial stiffening, and dysfunction in heart failure. The findings suggest that antibody-based inhibition of eCyPA may offer a novel therapeutic strategy for nonischemic heart failure. Further research is needed to evaluate the translational potential of these interventions in human patients with cardiac hypertrophy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39140165/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240814161035&v=2.18.0.post9+e462414">39140165</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324812>10.1161/CIRCRESAHA.124.324812</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39140165</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Manuel Sigle</dc:creator>
<dc:creator>Anne-Katrin Rohlfing</dc:creator>
<dc:creator>Melanie Cruz Santos</dc:creator>
<dc:creator>Timo Kopp</dc:creator>
<dc:creator>Konstantin Krutzke</dc:creator>
<dc:creator>Vincent Gidlund</dc:creator>
<dc:creator>Ferdinand Kollotzek</dc:creator>
<dc:creator>Julia Marzi</dc:creator>
<dc:creator>Saskia von Ungern-Sternberg</dc:creator>
<dc:creator>Antti Poso</dc:creator>
<dc:creator>Mathias Heikenwälder</dc:creator>
<dc:creator>Katja Schenke-Layland</dc:creator>
<dc:creator>Peter Seizer</dc:creator>
<dc:creator>Julia Möllmann</dc:creator>
<dc:creator>Nikolaus Marx</dc:creator>
<dc:creator>Robert Feil</dc:creator>
<dc:creator>Susanne Feil</dc:creator>
<dc:creator>Robert Lukowski</dc:creator>
<dc:creator>Oliver Borst</dc:creator>
<dc:creator>Tilman E Schäffer</dc:creator>
<dc:creator>Karin Anne Lydia Müller</dc:creator>
<dc:creator>Meinrad P Gawaz</dc:creator>
<dc:creator>David Heinzmann</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Targeting Cyclophilin A in the Cardiac Microenvironment Preserves Heart Function and Structure in Failing Hearts</dc:title>
<dc:identifier>pmid:39140165</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324812</dc:identifier>
</item>
<item>
<title>High expression of oleoyl-ACP hydrolase underpins life-threatening respiratory viral diseases</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39137778/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240814161035&amp;v=2.18.0.post9+e462414
      <description>Respiratory infections cause significant morbidity and mortality, yet it is unclear why some individuals succumb to severe disease. In patients hospitalized with avian A(H7N9) influenza, we investigated early drivers underpinning fatal disease. Transcriptomics strongly linked oleoyl-acyl-carrier-protein (ACP) hydrolase (OLAH), an enzyme mediating fatty acid production, with fatal A(H7N9) early after hospital admission, persisting until death. Recovered patients had low OLAH expression throughout...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 6:S0092-8674(24)00800-6. doi: 10.1016/j.cell.2024.07.026. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Respiratory infections cause significant morbidity and mortality, yet it is unclear why some individuals succumb to severe disease. In patients hospitalized with avian A(H7N9) influenza, we investigated early drivers underpinning fatal disease. Transcriptomics strongly linked oleoyl-acyl-carrier-protein (ACP) hydrolase (OLAH), an enzyme mediating fatty acid production, with fatal A(H7N9) early after hospital admission, persisting until death. Recovered patients had low OLAH expression throughout hospitalization. High OLAH levels were also detected in patients hospitalized with life-threatening seasonal influenza, COVID-19, respiratory syncytial virus (RSV), and multisystem inflammatory syndrome in children (MIS-C) but not during mild disease. In olah<sup>-/-</sup> mice, lethal influenza infection led to survival and mild disease as well as reduced lung viral loads, tissue damage, infection-driven pulmonary cell infiltration, and inflammation. This was underpinned by differential lipid droplet dynamics as well as reduced viral replication and virus-induced inflammation in macrophages. Supplementation of oleic acid, the main product of OLAH, increased influenza replication in macrophages and their inflammatory potential. Our findings define how the expression of OLAH drives life-threatening viral disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39137778/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240814161035&v=2.18.0.post9+e462414">39137778</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.026>10.1016/j.cell.2024.07.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39137778</guid>
<pubDate>Tue, 13 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Xiaoxiao Jia</dc:creator>
<dc:creator>Jeremy Chase Crawford</dc:creator>
<dc:creator>Deborah Gebregzabher</dc:creator>
<dc:creator>Ebony A Monson</dc:creator>
<dc:creator>Robert C Mettelman</dc:creator>
<dc:creator>Yanmin Wan</dc:creator>
<dc:creator>Yanqin Ren</dc:creator>
<dc:creator>Janet Chou</dc:creator>
<dc:creator>Tanya Novak</dc:creator>
<dc:creator>Hayley A McQuilten</dc:creator>
<dc:creator>Michele Clarke</dc:creator>
<dc:creator>Annabell Bachem</dc:creator>
<dc:creator>Isabelle J Foo</dc:creator>
<dc:creator>Svenja Fritzlar</dc:creator>
<dc:creator>Julio Carrera Montoya</dc:creator>
<dc:creator>Alice M Trenerry</dc:creator>
<dc:creator>Shuai Nie</dc:creator>
<dc:creator>Michael G Leeming</dc:creator>
<dc:creator>Thi H O Nguyen</dc:creator>
<dc:creator>Lukasz Kedzierski</dc:creator>
<dc:creator>Dene R Littler</dc:creator>
<dc:creator>Andrew Kueh</dc:creator>
<dc:creator>Tina Cardamone</dc:creator>
<dc:creator>Chinn Yi Wong</dc:creator>
<dc:creator>Luca Hensen</dc:creator>
<dc:creator>Aira Cabug</dc:creator>
<dc:creator>Jaime Gómez Laguna</dc:creator>
<dc:creator>Mona Agrawal</dc:creator>
<dc:creator>Tim Flerlage</dc:creator>
<dc:creator>David F Boyd</dc:creator>
<dc:creator>Lee-Ann Van de Velde</dc:creator>
<dc:creator>Jennifer R Habel</dc:creator>
<dc:creator>Liyen Loh</dc:creator>
<dc:creator>Hui-Fern Koay</dc:creator>
<dc:creator>Carolien E van de Sandt</dc:creator>
<dc:creator>Igor E Konstantinov</dc:creator>
<dc:creator>Stuart P Berzins</dc:creator>
<dc:creator>Katie L Flanagan</dc:creator>
<dc:creator>Linda M Wakim</dc:creator>
<dc:creator>Marco J Herold</dc:creator>
<dc:creator>Amanda M Green</dc:creator>
<dc:creator>Heather S Smallwood</dc:creator>
<dc:creator>Jamie Rossjohn</dc:creator>
<dc:creator>Ryan S Thwaites</dc:creator>
<dc:creator>Christopher Chiu</dc:creator>
<dc:creator>Nichollas E Scott</dc:creator>
<dc:creator>Jason M Mackenzie</dc:creator>
<dc:creator>Sammy Bedoui</dc:creator>
<dc:creator>Patrick C Reading</dc:creator>
<dc:creator>Sarah L Londrigan</dc:creator>
<dc:creator>Karla J Helbig</dc:creator>
<dc:creator>Adrienne G Randolph</dc:creator>
<dc:creator>Paul G Thomas</dc:creator>
<dc:creator>Jianqing Xu</dc:creator>
<dc:creator>Zhongfang Wang</dc:creator>
<dc:creator>Brendon Y Chua</dc:creator>
<dc:creator>Katherine Kedzierska</dc:creator>
<dc:date>2024-08-13</dc:date>
<dc:source>Cell</dc:source>
<dc:title>High expression of oleoyl-ACP hydrolase underpins life-threatening respiratory viral diseases</dc:title>
<dc:identifier>pmid:39137778</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.026</dc:identifier>
</item>
<item>
<title>Macrophage-mediated myelin recycling fuels brain cancer malignancy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39137777/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240814161035&amp;v=2.18.0.post9+e462414
      <description>Tumors growing in metabolically challenged environments, such as glioblastoma in the brain, are particularly reliant on crosstalk with their tumor microenvironment (TME) to satisfy their high energetic needs. To study the intricacies of this metabolic interplay, we interrogated the heterogeneity of the glioblastoma TME using single-cell and multi-omics analyses and identified metabolically rewired tumor-associated macrophage (TAM) subpopulations with pro-tumorigenic properties. These TAM...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 7:S0092-8674(24)00824-9. doi: 10.1016/j.cell.2024.07.030. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Tumors growing in metabolically challenged environments, such as glioblastoma in the brain, are particularly reliant on crosstalk with their tumor microenvironment (TME) to satisfy their high energetic needs. To study the intricacies of this metabolic interplay, we interrogated the heterogeneity of the glioblastoma TME using single-cell and multi-omics analyses and identified metabolically rewired tumor-associated macrophage (TAM) subpopulations with pro-tumorigenic properties. These TAM subsets, termed lipid-laden macrophages (LLMs) to reflect their cholesterol accumulation, are epigenetically rewired, display immunosuppressive features, and are enriched in the aggressive mesenchymal glioblastoma subtype. Engulfment of cholesterol-rich myelin debris endows subsets of TAMs to acquire an LLM phenotype. Subsequently, LLMs directly transfer myelin-derived lipids to cancer cells in an LXR/Abca1-dependent manner, thereby fueling the heightened metabolic demands of mesenchymal glioblastoma. Our work provides an in-depth understanding of the immune-metabolic interplay during glioblastoma progression, thereby laying a framework to unveil targetable metabolic vulnerabilities in glioblastoma.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39137777/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240814161035&v=2.18.0.post9+e462414">39137777</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.030>10.1016/j.cell.2024.07.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39137777</guid>
<pubDate>Tue, 13 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Daan J Kloosterman</dc:creator>
<dc:creator>Johanna Erbani</dc:creator>
<dc:creator>Menno Boon</dc:creator>
<dc:creator>Martina Farber</dc:creator>
<dc:creator>Shanna M Handgraaf</dc:creator>
<dc:creator>Masami Ando-Kuri</dc:creator>
<dc:creator>Elena Sánchez-López</dc:creator>
<dc:creator>Bauke Fontein</dc:creator>
<dc:creator>Marjolijn Mertz</dc:creator>
<dc:creator>Marja Nieuwland</dc:creator>
<dc:creator>Ning Qing Liu</dc:creator>
<dc:creator>Gabriel Forn-Cuni</dc:creator>
<dc:creator>Nicole N van der Wel</dc:creator>
<dc:creator>Anita E Grootemaat</dc:creator>
<dc:creator>Luuk Reinalda</dc:creator>
<dc:creator>Sander I van Kasteren</dc:creator>
<dc:creator>Elzo de Wit</dc:creator>
<dc:creator>Brian Ruffell</dc:creator>
<dc:creator>Ewa Snaar-Jagalska</dc:creator>
<dc:creator>Kevin Petrecca</dc:creator>
<dc:creator>Dieta Brandsma</dc:creator>
<dc:creator>Alexander Kros</dc:creator>
<dc:creator>Martin Giera</dc:creator>
<dc:creator>Leila Akkari</dc:creator>
<dc:date>2024-08-13</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Macrophage-mediated myelin recycling fuels brain cancer malignancy</dc:title>
<dc:identifier>pmid:39137777</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.030</dc:identifier>
</item>
<item>
<title>Correction to: Atherosclerosis in ancient mummified humans: the global HORUS study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39136624/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240814161035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 13:ehae536. doi: 10.1093/eurheartj/ehae536. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39136624/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240814161035&v=2.18.0.post9+e462414">39136624</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae536>10.1093/eurheartj/ehae536</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39136624</guid>
<pubDate>Tue, 13 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Atherosclerosis in ancient mummified humans: the global HORUS study</dc:title>
<dc:identifier>pmid:39136624</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae536</dc:identifier>
</item>
<item>
<title>Results of International, Double-Blind, Randomized, Placebo-Controlled, Phase IIa Study of Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment-Elevation Myocardial Infarction (STEMI)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39133774/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240814161035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 13;150(7):580-582. doi: 10.1161/CIRCULATIONAHA.124.069396. Epub 2024 Aug 12.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39133774/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240814161035&v=2.18.0.post9+e462414">39133774</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069396>10.1161/CIRCULATIONAHA.124.069396</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39133774</guid>
<pubDate>Mon, 12 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Antonio Abbate</dc:creator>
<dc:creator>Benjamin Van Tassell</dc:creator>
<dc:creator>Vlad Bogin</dc:creator>
<dc:creator>Roshanak Markley</dc:creator>
<dc:creator>Dmitry V Pevzner</dc:creator>
<dc:creator>Paul C Cremer</dc:creator>
<dc:creator>Imad Meray</dc:creator>
<dc:creator>Dmitry V Privalov</dc:creator>
<dc:creator>Angela Taylor</dc:creator>
<dc:creator>Sergey A Grishin</dc:creator>
<dc:creator>Alina N Egorova</dc:creator>
<dc:creator>Ekaterina G Ponomar</dc:creator>
<dc:creator>Yan Lavrovsky</dc:creator>
<dc:creator>Mikhail Yu Samsonov</dc:creator>
<dc:creator>RPH-104 STEMI Study Investigators</dc:creator>
<dc:date>2024-08-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Results of International, Double-Blind, Randomized, Placebo-Controlled, Phase IIa Study of Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment-Elevation Myocardial Infarction (STEMI)</dc:title>
<dc:identifier>pmid:39133774</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069396</dc:identifier>
</item>
<item>
<title>Cardio-Oncology: A New Clinical Frontier and Novel Platform for Cardiovascular Investigation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39133773/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240814161035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 13;150(7):513-515. doi: 10.1161/CIRCULATIONAHA.124.065473. Epub 2024 Aug 12.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39133773/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240814161035&v=2.18.0.post9+e462414">39133773</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.065473>10.1161/CIRCULATIONAHA.124.065473</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39133773</guid>
<pubDate>Mon, 12 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Javid J Moslehi</dc:creator>
<dc:date>2024-08-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardio-Oncology: A New Clinical Frontier and Novel Platform for Cardiovascular Investigation</dc:title>
<dc:identifier>pmid:39133773</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.065473</dc:identifier>
</item>
<item>
<title>Letter by Soltani-Kermanshahi Regarding Article, "ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39133772/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240814161035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Aug 13;150(7):e155. doi: 10.1161/CIRCULATIONAHA.124.069134. Epub 2024 Aug 12.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39133772/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240814161035&v=2.18.0.post9+e462414">39133772</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069134>10.1161/CIRCULATIONAHA.124.069134</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39133772</guid>
<pubDate>Mon, 12 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Mojtaba Soltani-Kermanshahi</dc:creator>
<dc:date>2024-08-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Soltani-Kermanshahi Regarding Article, "ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial"</dc:title>
<dc:identifier>pmid:39133772</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069134</dc:identifier>
</item>
<item>
<title>Pulmonary hypertension in heart failure: the good, the bad, and the ugly</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39132978/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240814161035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 12:ehae518. doi: 10.1093/eurheartj/ehae518. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39132978/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240814161035&v=2.18.0.post9+e462414">39132978</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae518>10.1093/eurheartj/ehae518</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39132978</guid>
<pubDate>Mon, 12 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Stephan Rosenkranz</dc:creator>
<dc:creator>Marius M Hoeper</dc:creator>
<dc:creator>Bradley A Maron</dc:creator>
<dc:date>2024-08-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pulmonary hypertension in heart failure: the good, the bad, and the ugly</dc:title>
<dc:identifier>pmid:39132978</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae518</dc:identifier>
</item>
<item>
<title>The DanGer Shock trial: a new dawn but much to uncover</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39132927/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240814161035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 12:ehae516. doi: 10.1093/eurheartj/ehae516. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39132927/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240814161035&v=2.18.0.post9+e462414">39132927</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae516>10.1093/eurheartj/ehae516</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39132927</guid>
<pubDate>Mon, 12 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Enzo Lüsebrink</dc:creator>
<dc:creator>Leonhard Binzenhöfer</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:date>2024-08-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The DanGer Shock trial: a new dawn but much to uncover</dc:title>
<dc:identifier>pmid:39132927</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae516</dc:identifier>
</item>
<item>
<title>The AORTA Gene score for detection and risk stratification of ascending aortic dilation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39132911/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240814161035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: A comprehensive model incorporating polygenic information and clinical risk factors explained 34.9%-41.8% of the variation in ascending aortic diameter, improving the identification of ascending aortic dilation and adverse thoracic aortic events compared to clinical risk factors.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 12:ehae474. doi: 10.1093/eurheartj/ehae474. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: This study assessed whether a model incorporating clinical features and a polygenic score for ascending aortic diameter would improve diameter estimation and prediction of adverse thoracic aortic events over clinical features alone.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Aortic diameter estimation models were built with a 1.1 million-variant polygenic score (AORTA Gene) and without it. Models were validated internally in 4394 UK Biobank participants and externally in 5469 individuals from Mass General Brigham (MGB) Biobank, 1298 from the Framingham Heart Study (FHS), and 610 from All of Us. Model fit for adverse thoracic aortic events was compared in 401 453 UK Biobank and 164 789 All of Us participants.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: AORTA Gene explained more of the variance in thoracic aortic diameter compared to clinical factors alone: 39.5% (95% confidence interval 37.3%-41.8%) vs. 29.3% (27.0%-31.5%) in UK Biobank, 36.5% (34.4%-38.5%) vs. 32.5% (30.4%-34.5%) in MGB, 41.8% (37.7%-45.9%) vs. 33.0% (28.9%-37.2%) in FHS, and 34.9% (28.8%-41.0%) vs. 28.9% (22.9%-35.0%) in All of Us. AORTA Gene had a greater area under the receiver operating characteristic curve for identifying diameter ≥ 4 cm: 0.836 vs. 0.776 (P &lt; .0001) in UK Biobank, 0.808 vs. 0.767 in MGB (P &lt; .0001), 0.856 vs. 0.818 in FHS (P &lt; .0001), and 0.827 vs. 0.791 (P = .0078) in All of Us. AORTA Gene was more informative for adverse thoracic aortic events in UK Biobank (P = .0042) and All of Us (P = .049).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A comprehensive model incorporating polygenic information and clinical risk factors explained 34.9%-41.8% of the variation in ascending aortic diameter, improving the identification of ascending aortic dilation and adverse thoracic aortic events compared to clinical risk factors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39132911/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240814161035&v=2.18.0.post9+e462414">39132911</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae474>10.1093/eurheartj/ehae474</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39132911</guid>
<pubDate>Mon, 12 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>James P Pirruccello</dc:creator>
<dc:creator>Shaan Khurshid</dc:creator>
<dc:creator>Honghuang Lin</dc:creator>
<dc:creator>Lu-Chen Weng</dc:creator>
<dc:creator>Siavash Zamirpour</dc:creator>
<dc:creator>Shinwan Kany</dc:creator>
<dc:creator>Avanthi Raghavan</dc:creator>
<dc:creator>Satoshi Koyama</dc:creator>
<dc:creator>Ramachandran S Vasan</dc:creator>
<dc:creator>Emelia J Benjamin</dc:creator>
<dc:creator>Mark E Lindsay</dc:creator>
<dc:creator>Patrick T Ellinor</dc:creator>
<dc:date>2024-08-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The AORTA Gene score for detection and risk stratification of ascending aortic dilation</dc:title>
<dc:identifier>pmid:39132911</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae474</dc:identifier>
</item>





























</channel>
</rss>